---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-069993"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:51:19.532061+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Pfizer terminates global license deal for Theravance's preclinical JAK inhibitor

## Summary
- Termination effective Oct 7, 2023; Pfizer gave notice June 9, 2023.
- Agreement covered preclinical skin-selective, locally acting pan-JAK inhibitor program.
- No reason for termination or financial impact disclosed by Theravance.
- Theravance regains rights to the program subject to wind-down obligations.

## SEC filing metadata
- accession: 0001104659-23-069993
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/0001104659-23-069993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/tm2318324d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-069993
- JSON: https://secwatch.observer/filing/0001104659-23-069993.json
- Plain text: https://secwatch.observer/filing/0001104659-23-069993.txt

## Key facts
- Material Agreements
  Theravance Biopharma, Inc. terminated Pfizer Agreement with Pfizer Inc. (effective 2023-10-07).
  - Action: termination
  - Agreement: license
  - Counterparty: Pfizer Inc.
  - Effective: 2023-10-07
  source text: On June 9 , 2023, the Company received notice from Pfizer terminating the Pfizer Agreement, effective as of October 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923069993/0001104659-23-069993-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.